Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients

References

• O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373: 1891–1904.
   PubMed Web of Science ®Google Scholar
• Touw DJ, Vinks AA, Mouton JW, . Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Clin Pharmacokinet 1998; 35: 437–459.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994; 26: 292–307.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight and age. Ther Drug Monit 2007; 29: 271–278.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Crom WR, Karlson KH Jr, Mallory GB Jr, Evans WE. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmacol Ther 1996; 59: 529–540.
   Google Scholar
• Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988; 35: 542–578.
   PubMed Web of Science ®Google Scholar
• Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J R Soc Med 1998; 91: 7–9.
   Google Scholar
• Minkes RK, Langer JC, Skinner A, . Intestinal obstruction after lung transplantation in children with cystic fibrosis. J Pediatr Surg 1999; 34: 1498–1493.
   Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360.
   PubMed Web of Science ®Google Scholar
• Keating GM. Posaconazole. Drugs 2005; 65: 1553–1567; discussion 1568–1569.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Umemura K, Kondo K, . Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75: 587–588.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, . Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–2553.
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, . Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572.
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, . Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.
   PubMed Web of Science ®Google Scholar
• Trifilio S, Ortiz R, Pennick G, . Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.
   PubMed Web of Science ®Google Scholar
• Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739–742.
   PubMed Web of Science ®Google Scholar
• Boussaud V, Daudet N, Billaud EM, . Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus. J Heart Lung Transplant 2008; 27: 229–232.
   Google Scholar
• Berge M, Guillemain R, Boussaud V, . Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009; 11: 211–219.
   PubMed Web of Science ®Google Scholar
• Berge M, Guillemain R, Lefeuvre S, . Posaconazole (PSZ) therapeutic drug monitoring (TDM) in cystic fibrosis (CF) lung transplant (LTx) patients. Abstract 1751, 19th ECCMID, Helsinki, 16–19 May 2009.
   Google Scholar
• Singh N, Limaye AP, Forrest G, . Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320–326.
   PubMed Web of Science ®Google Scholar
• Brüggemann RJ, Alffenaar JW, Blijlevens NM, . Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 144–1458.
   Google Scholar
• Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271–272.
   PubMed Web of Science ®Google Scholar
• Berge M, Chevalier P, Benammar M, . Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Ther Drug Monit 2009; 31: 396–399.
   PubMed Web of Science ®Google Scholar
• Wood N, Tan K, Purkins L, . Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl. 1): 56–61.
   Google Scholar
• Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis 2009; 48: 839.
   PubMed Web of Science ®Google Scholar
• Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348–2350.
   PubMed Web of Science ®Google Scholar
• Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167–172.
   PubMed Web of Science ®Google Scholar
• Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21: 580–586.
   PubMed Web of Science ®Google Scholar